Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech focused on developing RNA interference therapies for KRAS-driven cancers, has announced its participation in the Noble Capital Markets 20th Annual Emerging Growth Equity Conference. The event will take place December 3-4, 2024, in Boca Raton, Florida.
CEO Ilan Hadar will present "Transforming Cancer Care: Silexion Therapeutics' Innovative Approach to Pancreatic Cancer" on December 4 at 11:30 am. A replay will be available on the company's website. Management will also be available for one-on-one meetings with interested investors during the conference.
Silexion Therapeutics (NASDAQ: SLXN), una biotech in fase clinica focalizzata nello sviluppo di terapie di interferenza RNA per tumori guidati da KRAS, ha annunciato la sua partecipazione alla 20a Conferenza Annuale sulle Crescite Emergenti di Noble Capital Markets. L'evento si terrà il 3 e 4 dicembre 2024 a Boca Raton, Florida.
Il CEO Ilan Hadar presenterà "Trasformare la Cura del Cancro: L'Innovativo Approccio di Silexion Therapeutics al Cancro Pancreatico" il 4 dicembre alle 11:30. Una registrazione sarà disponibile sul sito web dell'azienda. La direzione sarà anche disponibile per incontri individuali con investitori interessati durante la conferenza.
Silexion Therapeutics (NASDAQ: SLXN), una biotecnológica en etapa clínica centrada en el desarrollo de terapias de interferencia de ARN para cánceres impulsados por KRAS, ha anunciado su participación en la 20ª Conferencia Anual de Crecimiento Emergente de Noble Capital Markets. El evento se llevará a cabo el 3 y 4 de diciembre de 2024 en Boca Raton, Florida.
El CEO Ilan Hadar presentará "Transformando el Cuidado del Cáncer: El Enfoque Innovador de Silexion Therapeutics para el Cáncer de Páncreas" el 4 de diciembre a las 11:30 am. Una grabación estará disponible en el sitio web de la empresa. La dirección también estará disponible para reuniones uno a uno con inversores interesados durante la conferencia.
실렉시온 테라퓨틱스 (NASDAQ: SLXN)는 KRAS 유도 암을 위한 RNA 간섭 치료 개발에 초점을 맞춘 임상 단계 생명공학 회사로, 노블 캐피탈 마켓 20회 연례 신흥 성장 주식 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 12월 3일과 4일, 플로리다 주 보카 라톤에서 개최됩니다.
CEO 일란 하다르가 12월 4일 오전 11시 30분에 "암 치료의 변화: 실렉시온 테라퓨틱스의 혁신적인 췌장암 접근법"을 발표할 예정입니다. 회사 웹사이트에서 재생이 가능할 것입니다. 경영진은 컨퍼런스 동안 관심 있는 투자자들과의 일대일 미팅에도 참여할 예정입니다.
Silexion Therapeutics (NASDAQ: SLXN), une biotechnologie en phase clinique axée sur le développement de thérapies d'interférence par ARN pour les cancers induits par KRAS, a annoncé sa participation à la 20ème Conférence Annuelle sur les Croissances Émergentes de Noble Capital Markets. L'événement se tiendra les 3 et 4 décembre 2024 à Boca Raton, en Floride.
Le PDG Ilan Hadar présentera "Transformer la Prise en Charge du Cancer : L'Approche Innovante de Silexion Therapeutics pour le Cancer du Pancréas" le 4 décembre à 11h30. Une rediffusion sera disponible sur le site internet de l'entreprise. La direction sera également disponible pour des réunions individuelles avec des investisseurs intéressés pendant la conférence.
Silexion Therapeutics (NASDAQ: SLXN), ein in der klinischen Phase befindliches Biotech-Unternehmen, das sich auf die Entwicklung von RNA-Interferenz-Therapien für von KRAS gesteuerte Krebsarten konzentriert, hat seine Teilnahme an der 20. jährlichen Emerging Growth Equity Conference von Noble Capital Markets bekannt gegeben. Die Veranstaltung findet am 3. und 4. Dezember 2024 in Boca Raton, Florida, statt.
CEO Ilan Hadar wird am 4. Dezember um 11:30 Uhr "Transforming Cancer Care: Silexion Therapeutics' Innovative Approach to Pancreatic Cancer" präsentieren. Ein Mitschnitt wird auf der Unternehmenswebsite verfügbar sein. Die Geschäftsführung steht während der Konferenz auch für individuelle Gespräche mit interessierten Investoren zur Verfügung.
- None.
- None.
GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that the Company’s management will be attending and presenting at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference taking place December 3-4, 2024, in Boca Raton, Florida.
Ilan Hadar, Chief Executive Officer will deliver a company presentation titled “Transforming Cancer Care: Silexion Therapeutics’ Innovative Approach to Pancreatic Cancer” on December 4, 2024 at 11:30 am. A replay of the presentation will be posted, when available, to Silexion’s website on the Presentation & Events page of the investors section.
The Company’s management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact the Noble investor outreach team to schedule a meeting.
About Silexion Therapuetics
Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com
Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Investor Contact
ARX | Capital Markets Advisors
North American Equities Desk
silexion@arxadvisory.com
FAQ
When is Silexion Therapeutics (SLXN) presenting at the Noble Capital Markets Conference?
What is the topic of Silexion Therapeutics' (SLXN) presentation at the Noble Conference 2024?
Will there be a replay available of Silexion's (SLXN) Noble Conference presentation?
What type of therapies is Silexion Therapeutics (SLXN) developing?
